MGO One Seven LLC lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 4.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,493 shares of the biopharmaceutical company’s stock after selling 540 shares during the quarter. MGO One Seven LLC’s holdings in Halozyme Therapeutics were worth $401,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in HALO. Vanguard Group Inc. boosted its stake in shares of Halozyme Therapeutics by 0.3% during the third quarter. Vanguard Group Inc. now owns 13,335,155 shares of the biopharmaceutical company’s stock valued at $527,273,000 after acquiring an additional 38,342 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in Halozyme Therapeutics by 16.5% in the 4th quarter. Artisan Partners Limited Partnership now owns 7,140,953 shares of the biopharmaceutical company’s stock worth $406,320,000 after buying an additional 1,013,061 shares during the last quarter. Macquarie Group Ltd. boosted its stake in Halozyme Therapeutics by 2.0% in the 4th quarter. Macquarie Group Ltd. now owns 2,605,261 shares of the biopharmaceutical company’s stock worth $148,239,000 after buying an additional 50,294 shares during the last quarter. Geode Capital Management LLC boosted its stake in Halozyme Therapeutics by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 2,515,097 shares of the biopharmaceutical company’s stock worth $143,109,000 after buying an additional 38,233 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Halozyme Therapeutics by 1.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,637,959 shares of the biopharmaceutical company’s stock worth $93,199,000 after buying an additional 22,939 shares during the last quarter. Hedge funds and other institutional investors own 92.93% of the company’s stock.
Halozyme Therapeutics Stock Up 0.3 %
NASDAQ HALO opened at $43.86 on Tuesday. The stock has a market cap of $5.79 billion, a PE ratio of 25.65, a P/E/G ratio of 0.66 and a beta of 1.24. Halozyme Therapeutics, Inc. has a fifty-two week low of $29.85 and a fifty-two week high of $59.46. The business has a 50 day moving average price of $38.53 and a two-hundred day moving average price of $39.12. The company has a quick ratio of 5.44, a current ratio of 6.58 and a debt-to-equity ratio of 9.91.
Analyst Ratings Changes
Check Out Our Latest Report on Halozyme Therapeutics
Insiders Place Their Bets
In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $42.69, for a total value of $426,900.00. Following the transaction, the chief executive officer now directly owns 623,666 shares of the company’s stock, valued at approximately $26,624,301.54. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 30,000 shares of company stock worth $1,191,200 in the last 90 days. 2.30% of the stock is owned by company insiders.
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- 3 Sizzling Dividends That Are Going On Sale
- How to Use the MarketBeat Dividend Calculator
- 3 Ways To Trade, Trade Desk Stock Post Earnings
- How to Analyze Restaurant Stocks
- Inflation, The Fed, and Oil Prices: Interest Rates Are Going Up
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
